Nexgel Inc Revenue Growth Rates (NXGL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Nexgel Inc   (NASDAQ: NXGL)
 

NXGL's Revenue Growth by Quarter and Year

Nexgel Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NXGL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 3.69
1st Quarter March 2.06
FY 5.75

NXGLs Annual Revenue
Nexgel Inc 's Revenue in the fiscal year 2025 $ 10.51 millions
Nexgel Inc 's Revenue in the fiscal year 2024 $ 7.75 millions
Nexgel Inc 's Revenue in the fiscal year 2023 $ 3.62 millions
Nexgel Inc 's Revenue in the fiscal year 2022 $ 2.05 millions
Nexgel Inc 's Revenue in the fiscal year 2021 $ 1.55 millions




NXGL Revenue second quarter 2026 Y/Y Growth Comment
Nexgel Inc reported Revenue surge of 63.1% year on year in the second quarter 2026, to $ 3.69 millions, this is lower than Nexgel Inc 's recent average Revenue rise of 76.11%.

Looking into second quarter 2026 results within Medical Equipment & Supplies industry 91 other companies have achieved higher Revenue growth. While Nexgel Inc ' s Revenue jump of 63.1% ranks overall at the positon no. 1414 in the second quarter 2026.


NXGL Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 36.92 % 158.33 % 107.69 %
3rd Quarter September - -1.75 % 86.89 % 114.04 %
2nd Quarter June 63.1 % 60.28 % 20.51 % 108.93 %
1st Quarter March -5.94 % 72.44 % 104.84 % 55 %
FY   - 35.61 % 89.49 % -

Financial Statements
Nexgel Inc 's second quarter 2026 Revenue $ 3.69 millions NXGL's Income Statement
Nexgel Inc 's second quarter 2025 Revenue $ 2.26 millions Quarterly NXGL's Income Statement


NXGL Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 70.54 % 22.37 % -11.48 %
3rd Quarter September - -0.88 % 61.7 % 4.27 %
2nd Quarter June 78.93 % 3.2 % 11.02 % 88.71 %
1st Quarter March -46.07 % -21.51 % 17.59 % 19.23 %
FY (Year on Year)   - 35.61 % 89.49 % -


Back to NXGL Growth rate Comparisons >> Back to NXGL Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #92
Healthcare Sector #244
Overall #1414

Revenue Y/Y Growth Statistics
High Average Low
124.78 % 76.11 % 19.75 %
(Jun 30 2024)   (Mar 31 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #92
Healthcare Sector #244
Overall #1414
Revenue Y/Y Growth Statistics
High Average Low
124.78 % 76.11 % 19.75 %
(Jun 30 2024)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Nexgel Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
187.64 % 20.68 % -100 %
(Dec 31 2018)  


NXGL's II. Quarter Q/Q Revenue Comment
Nexgel Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 78.93%, to $ 3.69 millions, from $2.06 millions in the first quarter.
NXGL is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Equipment & Supplies industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Nexgel Inc 's Revenue growth quarter on quarter, overall rank is 170.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #12
Healthcare Sector #49
Overall #170
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #12
Healthcare Sector #49
Overall #170
Revenue Q/Q Growth Statistics
High Average Low
187.64 % 20.68 % -100 %
(Dec 31 2018)  


NXGL's II. Quarter Q/Q Revenue Comment
Nexgel Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 78.93%, to $ 3.69 millions, from $2.06 millions in the first quarter.
NXGL is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Equipment & Supplies industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Nexgel Inc 's Revenue growth quarter on quarter, overall rank is 170.


Nexgel Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 11.81 $ 10.38 $ 10.51 $ 9.48 $ 9.52
Y / Y Revenue Growth (TTM) 24.08 % 19.75 % 35.64 % 56.94 % 91.16 %
Year on Year Revenue Growth Overall Ranking # 171 # 129 # 94 # 62 # 77
Seqeuential Revenue Change (TTM) 13.75 % -1.21 % 10.87 % -0.41 % 9.78 %
Seq. Revenue Growth (TTM) Overall Ranking # 1414 # 1153 # 494 # 579 # 625


Cumulative Revenue growth Comment
Although Nexgel Inc 's Annual Revenue growth year on year were below company's average 76.11% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 24.08% year on year, from 19.75% in Mar 31 2026.

In the Healthcare sector 53 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 129 to 171.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 92
Healthcare Sector # 54
Overall # 171

Revenue TTM Y/Y Growth Statistics
High Average Low
124.78 %
 76.11 %
19.75 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 92
Sector # 244
S&P 500 # 1414
Cumulative Revenue growth Comment
Although Nexgel Inc 's Annual Revenue growth year on year were below company's average 76.11% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 24.08% year on year, from 19.75% in Mar 31 2026.

In the Healthcare sector 53 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 129 to 171.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 92
Healthcare Sector # 54
Overall # 171

Revenue TTM Y/Y Growth Statistics
High Average Low
124.78 %
76.11 %
19.75 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 92
Sector # 244
S&P 500 # 1414




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NXGL's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions


About Nexgel Inc Revenue Growth Rates (NXGL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Nexgel Inc (CIK 1468929).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-038555
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Nexgel Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.